Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
http://www.priceseries.com/trade/NKTR-Nektar-Therapeutics-stock-gains-27-percent-a-Trade-Record-by-priceSeries-2021012520210222.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments